If the disease is in the lungs, why deliver the drugs everywhere else?
Oral antifibrotics require high systemic dosing to achieve lung exposure, driving toxicity, discontinuation, and limiting the feasibility of combination therapy.
eSpraye is addressing that bottleneck with dry-powder inhaled fixed-dose combinations, co-forming multiple APIs into a single 1–5 μm particle delivered directly to the lung. The approach enables:
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
